Financial Data and Key Metrics Changes - Revenue for 2025 increased by 20% to approximately $2.2 million, compared to $1.86 million in 2024. Excluding a temporary revenue impact from transitioning to direct management of Amazon sales, full-year revenue growth would have been closer to 30% [6][10] - Gross margin improved to 62.5% from 54.1% in 2024, reflecting an improved product mix and a growing contribution from e-commerce channels [10] - The company reported a net loss of $6.4 million for 2025, compared to a net loss of $6.2 million in 2024. Adjusted net loss for the year would have been approximately $5.6 million when excluding one-time legal expenses [10][11] - Adjusted EBITDA loss improved to $5.3 million compared to $5.8 million in 2024 [11] - The company ended the year with $8.6 million in cash and short-term investments, providing a solid operating runway [11] Business Line Data and Key Metrics Changes - E-commerce revenue increased by 88%, driven by strong growth on Amazon and the direct-to-consumer website, now representing more than half of total revenue [7][8] - Municipal markets are seeing increased interest in fertility control approaches, with ongoing programs in cities like New York and Chicago [8][9] Market Data and Key Metrics Changes - Internationally, the company expanded its footprint with regulatory approvals in New Zealand and new distribution relationships in Belize [9] - The company is in discussions with potential deployment partners in New York City as the trial of Evolve concludes [9] Company Strategy and Development Direction - The company's core strategy remains focused on delivering current initiatives, scaling areas with traction, and maintaining resource allocation discipline [5] - The board is engaged in finding a new CEO to help scale the business and build on progress made [4][5] - The company aims to maintain financial discipline while investing in areas with traction, including e-commerce expansion and municipal adoption [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about accelerating growth in 2026, aiming for higher growth rates than 2025 [13] - The company is focused on a mixture of revenue contributors, including e-commerce, municipal orders, and international expansion [15][17] - Management is confident in the potential for improvement in profitability and revenue growth [45] Other Important Information - The legal dispute with Liphatech has been resolved satisfactorily, with all litigation dismissed [10][22] - The company is preparing for a significant year ahead, with expectations for growth in various markets [74] Q&A Session Summary Question: Should we expect similar growth rates in 2026 as in 2025? - Management indicated that growth could be higher, aiming to accelerate growth in profitable areas [13] Question: What will contribute to 2026 revenues? - A mixture of e-commerce, municipal orders, and international expansion is expected to drive revenue [15] Question: What is the status of the court case with Liphatech? - The case has been settled satisfactorily, and the company considers it a past issue [22] Question: What is the status of product registration in Australia? - Regulatory authorities are expected to provide a response in the spring [25] Question: Will the new CEO have incentives based on stock performance? - Yes, a meaningful portion of the CEO's compensation is expected to be equity-based [56] Question: How is the agricultural sector performing? - The agricultural sector is performing well, with expansions in various areas including almond groves and poultry [33] Question: What municipalities besides New York City are evaluating Evolve? - Baltimore and Chicago are mentioned, with ongoing assessments in various neighborhoods [32] Question: Will the sales team be expanded? - Yes, the company plans to expand the sales team to maximize B2B sales efforts [61]

SAFE HARBOR DISCLAIMER • This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predi ...

Core Insights - Fairlife has become a significant growth driver for The Coca-Cola Company, positioning it strongly in the expanding protein and functional nutrition market as consumer preferences shift towards healthier options [1][8] - Coca-Cola's investment in expanding Fairlife's production capacity is crucial for meeting demand and supporting volume growth, enhancing its innovation capabilities in protein shakes and value-added dairy [2][3] - Fairlife provides Coca-Cola with a competitive advantage in the health and wellness trend, offering strong pricing power and repeat purchase behavior, which helps balance slower growth in traditional categories [3] Company Strategies - Coca-Cola is focusing on expanding Fairlife's production capacity to alleviate supply constraints and drive higher volumes, which is expected to enhance its market position in health-focused beverages [2][8] - The company is strategically pivoting from carbonated drinks to higher-margin nutrition-led categories, reflecting a broader trend in consumer preferences towards better-for-you beverages [1][3] Competitive Landscape - In the competitive beverage market, PepsiCo and Keurig Dr Pepper are also targeting the protein and functional nutrition space, with PepsiCo leveraging its diverse portfolio and distribution strengths [4][5] - Keurig Dr Pepper is adopting a more measured approach, focusing on selective partnerships and functional beverages while minimizing capital investment, positioning itself to adapt to evolving consumer trends [6] Financial Performance - Coca-Cola's shares have increased by 12.1% over the past three months, slightly underperforming the industry growth of 14.2% [7] - The forward price-to-earnings ratio for Coca-Cola is 24.27X, which is higher than the industry average of 20.16X, indicating a premium valuation [9] - The Zacks Consensus Estimate projects year-over-year earnings growth of 3.8% for 2025 and 8.1% for 2026, with recent estimates remaining unchanged [10]

Core Viewpoint - SenesTech, Inc. is initiating a search for a new CEO as current CEO Joel Fruendt plans to retire, with Dr. Jamie Bechtel appointed as Interim Executive Chair to support the transition [1][3]. Group 1: Leadership Transition - Joel Fruendt, who joined SenesTech in 2022, has informed the Board of his intent to retire, and he will remain in his position until a successor is found or until June 30, 2026 [1][2]. - The Board will engage an executive search firm to assist in identifying a qualified successor for the CEO role [4]. Group 2: Interim Leadership - Dr. Jamie Bechtel has been appointed as Interim Executive Chair to support the management team during the transition, focusing on strategic alignment and communication [3][4]. - The current COO Michael Edell and CFO Tom Chesterman will continue to lead day-to-day operations during this transitional period [4]. Group 3: Company Mission and Products - SenesTech is dedicated to humane pest management through fertility control, with its flagship product Evolve® aimed at enhancing pest management effectiveness while reducing reliance on traditional poisons [5]. - The company's mission is to create healthier environments, cleaner cities, and more efficient businesses through sustainable solutions [5].

Company Overview - InMode is a leading global provider of minimally-invasive aesthetic and wellness solutions [5] - The company has 10 patented technologies across 11 product families [7] - InMode sells its products in 88 countries [7] - The company has 656 employees worldwide, including 284 direct sales reps [19] Financial Performance (Q3 2025) - Q3 2025 revenue was $93.2 million [7] - Non-GAAP net income for Q3 2025 was $24.5 million [7] - Non-GAAP gross margin for Q3 2025 was 78% [7] - Non-GAAP diluted earnings per share for Q3 2025 was $0.38 [7] Technology and Market - InMode addresses the "Treatment Gap" with minimally-invasive technologies [26] - RFAL technology can achieve up to 40% soft tissue contraction [40]

Summary of SenesTech Investor Conference Company Overview - **Company Name**: SenesTech - **Ticker Symbol**: SNES - **Industry**: Rodent Control Solutions - **Key Product**: Evolve (rodent birth control product) Core Industry Insights - Rodents are a significant public health issue, causing over **$27 billion** in infrastructure damage annually in the U.S. alone and destroying nearly **20%** of the world's food supply [2][3] - The global market for rodenticides is approximately **$4.5 billion**, with the U.S. market spending over **$1 billion** annually [11][23] - Traditional rodenticides are facing increasing resistance and regulatory restrictions, leading to a demand for humane and sustainable alternatives [10][24] Key Product Features and Innovations - SenesTech's products are the only registered rodent birth control solutions available commercially, focusing on suppressing rodent reproduction rather than just extermination [2][5] - The product **Evolve** has become the top-selling item, significantly changing the company's trajectory and expanding market reach [7][8] - Evolve has shown to reduce rat populations by **90%** when integrated into pest management programs [6][8] Financial Performance - **2024 Revenue Growth**: Up **56%**, driven by a **107%** increase in e-commerce sales due to Evolve [8][25] - **Gross Margin**: Improved to **65%** in Q2 2025, up from **54%** in the previous year [18][25] - **Revenue Breakdown**: E-commerce accounted for **56%** of Q2 sales, with a **78%** increase year-over-year [16][17] Market Strategy and Expansion - SenesTech is targeting multiple verticals: consumer, cities and governments, pest management, agribusiness, facilities management, and industrial applications [11][24] - The company has established a multi-channel distribution strategy, with **60%** of revenue coming from e-commerce platforms like Amazon and Walmart [11][12] - Recent municipal deployments in cities like Chicago and New York City are expected to drive future growth [14][15] Regulatory and Competitive Advantages - SenesTech has a regulatory head start with **EPA** approvals and a **FIFRA 25(b)** exemption, which competitors will find challenging to replicate [9][10] - The company holds proprietary know-how and has conducted extensive efficacy studies, establishing a strong competitive position in the market [9][10] Future Outlook - The company aims to achieve profitability with a break-even point estimated at **$6.5 to $7 million** in annual revenues [20][25] - Continued focus on operational efficiencies and growth in e-commerce, municipal, and international markets is expected to drive revenue [23][24] Additional Insights - The introduction of Evolve has allowed SenesTech to expand its market to include mice, enhancing growth opportunities [23] - The company has reduced cash burn by **$2 million** annually and is prioritizing investments in e-commerce and government sales [24][25]

Core Viewpoint - Eguana Technologies Inc. reported significant financial growth in Q2 2025, driven by increased utility engagements and favorable changes in investment tax credit rules in the USA, positioning the company for further advancements in energy storage technology [3][4]. Financial Performance - Q2 2025 revenue reached $0.9 million, marking a 426% increase compared to Q2 2024, with total revenue for the first half of 2025 at $1.9 million, a 407% increase from $0.5 million in the same period last year [4]. - Gross margin for Q2 2025 was approximately $424,934, representing a 44% improvement from a negative gross margin of $62,781 in Q2 2024, with a total gross margin of $886,108 for the first half of 2025, reflecting a 46% improvement [4]. - The operating loss for Q2 2025 was $698,385, a reduction from $1,590,267 in Q2 2024, while the net loss for the first half of 2025 was $1,263,835, a 58% improvement from $3,116,992 in the same period last year [4]. Business Developments - The company is actively engaging in utility projects across Canada, with ongoing and planned projects in British Columbia, Alberta, Ontario, and Nova Scotia, utilizing Canadian technology to enhance the distributed grid [3]. - Eguana has successfully entered the California demand response market and is continuing shipments to its Western Canadian utility partner for feeder improvement projects, with new orders anticipated in Q4 [5]. - The company has been awarded a development contract supported by federal and municipal funds to enhance the Eguana Edge platform and demonstrate solutions in commercial building applications [13]. Strategic Partnerships - Eguana has partnered with ITOCHU Corporation to extend the end date of its convertible debenture to November 30, 2025, allowing for further negotiations on a long-term solution [4]. - A partnership with a US-based provider of third-party finance for utility infrastructure is being developed, aimed at eliminating capital requirements for utilities and homeowners [13].

Summary of SenesTech (SNES) Conference Call - August 19, 2025 Company Overview - **Company**: SenesTech - **Ticker Symbol**: SNES - **Industry**: Biotech and Life Sciences, specifically pest control - **Core Product**: Rodent birth control solutions disrupting the rodenticide market, focusing on sustainable pest management [3][4] Key Points and Arguments Industry Context - **Rodent Problem**: Rodents cause over $27 billion in infrastructure damage annually in the U.S. and destroy nearly 20% of the world's food supply [4][5] - **Current Solutions**: Existing rodenticides are largely poisons that are ineffective and harmful, leading to resistance and bans in various jurisdictions [6][7] Product Differentiation - **Unique Approach**: SenesTech focuses on suppressing rodent reproduction rather than increasing mortality rates, with products that are humane and do not harm non-target species [11][12] - **Evolve Product**: Launched as a solid bait, it has an 18-month shelf life and is designed for both professional and DIY use, significantly expanding market reach [16][17] Market Position and Competitive Advantage - **Regulatory Head Start**: SenesTech has a FIFRA 25B minimum risk exemption and approvals in 48 states, giving it a significant advantage over competitors [18][19] - **Intellectual Property**: The company holds patents and trade secrets that protect its unique formulations and efficacy studies [20][21] Market Opportunities - **Market Size**: The U.S. rodenticide market is approximately $1 billion, with a global market of $4.5 billion [26][63] - **Target Verticals**: Key markets include consumers, cities and governments, pest management, agribusiness, facilities management, and food production [26][27] Sales and Distribution Strategy - **E-commerce Growth**: E-commerce accounts for over 60% of revenue, with a 78% increase year-over-year, driven by the popularity of Evolve [31][32] - **Municipal Deployments**: Significant traction in cities like Chicago and New York, with successful pilot programs leading to reorders and increased consumer adoption [36][38] Financial Performance - **Revenue Growth**: Total revenue is approximately $2 million annually, with Evolve sales increasing by 94%, making up 83% of second-quarter sales [51][52] - **Gross Margins**: Improved to 65.4% in Q2, driven by the profitability of the Evolve product [55] - **Cash Position**: The company ended the quarter with $6.1 million in cash, with a pro forma cash position of about $12 million, providing a runway into 2027 [60][61] Future Outlook - **Regulatory Tailwinds**: Increasing bans on traditional rodenticides and a push for humane alternatives create a favorable environment for SenesTech's products [63][64] - **Growth Strategy**: Focus on e-commerce, international markets, and government sales, with expectations for strong revenue growth and margin expansion [66][67] Additional Important Points - **International Expansion**: Successful pilot programs in markets like Hong Kong and the Netherlands, with potential for significant orders [43][44] - **Brick and Mortar Retail**: Recent agreements with distributors to expand into physical retail, with a nearly 500% increase in brick-and-mortar sales sequentially [46][47] This summary encapsulates the key insights from the SenesTech conference call, highlighting the company's innovative approach to pest control, market opportunities, and financial performance.

Core Insights - Gatorade recognizes exceptional high school athletes through its Player of the Year awards, celebrating their achievements in sports and community involvement [2][4][11] - The 2024-25 Gatorade Best Player of the Year winners are Cameron Boozer in boys basketball and Jane Hedengren in cross country and track & field, both of whom have demonstrated outstanding athletic performance and leadership [4][5][11] Gatorade Player of the Year Awards - The awards culminated in a week-long event in Los Angeles, featuring experiences such as meeting sports heroes, community service, and participation in educational events [2][3] - The event highlighted Gatorade's 60-year legacy in sports science, providing athletes with personalized insights on hydration and fueling needs [3] Athlete Achievements - Cameron Boozer, a senior power forward, led his team to a 30-3 record, averaging 22.1 points, 11.8 rebounds, and winning multiple accolades including the Naismith Trophy Award semifinalist [4][6] - Jane Hedengren, a senior distance runner, set multiple national high school records and won significant titles in cross country and track & field, including a course-record time at the Nike Cross Nationals [5][6] Gatorade Portfolio and PepsiCo - The Gatorade Portfolio, part of PepsiCo, includes brands like Propel and Muscle Milk, focusing on a comprehensive range of performance and wellness products for athletes [8] - PepsiCo reported nearly $92 billion in net revenue in 2024, driven by a diverse portfolio of beverages and convenient foods [9]

Summary of SenesTech (SNES) 2025 Conference Call Company Overview - **Company**: SenesTech, a biotech and life sciences company focused on rodent control through reproductive management rather than lethal methods [5][6] - **Ticker Symbol**: SNES, traded on NASDAQ [4] Core Product and Market Strategy - **Flagship Product**: Evolve, launched in 2024, is a soft bait designed for rodent fertility control, which has quickly become the top-selling product [12][14] - **Sales Growth**: Evolve sales grew by 40% year-over-year in Q1 2025 [15][37] - **Market Opportunity**: The U.S. rodenticide market is estimated at $1 billion annually, with a global market of $4.5 billion [34] Unique Selling Proposition - **Sustainable Approach**: Focus on controlling the birth rate of rodents rather than relying on poisons, which have social, political, and ecological drawbacks [6][8][30] - **Product Safety**: Evolve is designated as a minimum risk product by the EPA, using cottonseed oil as the active ingredient, making it safer for pets and wildlife [14][16] Distribution Channels - **Six Channel Strategy**: Includes e-commerce, agriculture distributors, pest management distributors, retail (e.g., Ace Hardware), international distributors, and direct sales to large customers [18][19] - **E-commerce Growth**: E-commerce sales increased by over 7%, with a run rate approaching $60,000 to $70,000 per month [20][21] Municipal and International Opportunities - **Municipal Deployments**: Significant projects in Chicago and New York City, with repeat orders indicating product effectiveness [23][24][25] - **International Expansion**: Exclusive distribution agreements signed in 12 countries, with expected approvals in Australia and New Zealand [27][28] Financial Performance - **Revenue Growth**: Record revenue of $1.9 million in 2024, up 56% from the previous year [39] - **Gross Margin Improvement**: Gross margins for Evolve reached 64%, compared to 32% in Q1 of the previous year [40] - **Cost Optimization**: Initiatives to reduce operating costs include pausing new product development and optimizing sales efforts [44] Future Outlook - **Path to Profitability**: Aiming for cash flow breakeven at approximately $1.5 million per quarter, with current revenues around $500,000 per quarter [45][46] - **Market Trends**: Increasing awareness of the need for humane rodent control solutions due to public health concerns and regulatory changes [52][53] Key Takeaways - **Transformative Opportunity**: SenesTech believes it has a paradigm-changing product that addresses long-standing rodent control issues in a sustainable manner [55][56] - **Execution Strategy**: Focus on expanding market presence, improving product offerings, and enhancing operational efficiencies to drive future growth [54][56]